Algert Global LLC Purchases 16,292 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Algert Global LLC boosted its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 59.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,592 shares of the company’s stock after buying an additional 16,292 shares during the period. Algert Global LLC owned about 0.07% of Twist Bioscience worth $1,969,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Thrivent Financial for Lutherans bought a new stake in Twist Bioscience in the third quarter valued at about $43,992,000. Point72 Asset Management L.P. grew its stake in shares of Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after purchasing an additional 613,057 shares during the period. Fred Alger Management LLC grew its stake in shares of Twist Bioscience by 720.7% in the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after purchasing an additional 575,080 shares during the period. Victory Capital Management Inc. lifted its position in shares of Twist Bioscience by 4,133.1% during the 2nd quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after buying an additional 300,891 shares during the period. Finally, Farallon Capital Management LLC bought a new stake in Twist Bioscience in the second quarter valued at $9,462,000.

Wall Street Analysts Forecast Growth

TWST has been the subject of several recent analyst reports. Scotiabank increased their price objective on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Leerink Partners increased their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Evercore ISI upped their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Barclays dropped their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Finally, TD Cowen reissued a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.00.

Twist Bioscience Price Performance

TWST stock opened at $48.32 on Thursday. The company has a 50 day moving average price of $43.75 and a 200 day moving average price of $46.20. Twist Bioscience Co. has a fifty-two week low of $23.07 and a fifty-two week high of $60.90. The stock has a market capitalization of $2.87 billion, a PE ratio of -13.42 and a beta of 1.78.

Insider Activity

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,730 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $46.94, for a total value of $81,206.20. Following the transaction, the chief executive officer now directly owns 495,523 shares of the company’s stock, valued at approximately $23,259,849.62. This trade represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Chess sold 3,600 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $47.26, for a total transaction of $170,136.00. Following the sale, the director now owns 21,641 shares of the company’s stock, valued at $1,022,753.66. The trade was a 14.26 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 98,118 shares of company stock valued at $4,391,151. Company insiders own 3.92% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.